Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
KRAS inhibitor |
| gptkbp:alsoKnownAs |
gptkb:adagrasib
|
| gptkbp:approvedBy |
2022
|
| gptkbp:ATCCode |
L01EG04
|
| gptkbp:CASNumber |
2389149-74-5
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Mirati_Therapeutics
|
| gptkbp:hasInChIKey |
QZJXODQKZQJZQJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C32H35ClFN7O2
|
| gptkbp:hasSMILES |
CC1=CC2=C(C=C1)N=C(N2)N3CCN(CC3)C(=O)C4=CC=C(C=C4)Cl
|
| https://www.w3.org/2000/01/rdf-schema#label |
MRTX849
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
colorectal cancer |
| gptkbp:mechanismOfAction |
covalent inhibitor of KRAS G12C
|
| gptkbp:molecularWeight |
604.1 g/mol
|
| gptkbp:PubChem_CID |
134584744
CHEMBL4297597 |
| gptkbp:regulates |
approved
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue liver enzyme elevation |
| gptkbp:target |
KRAS G12C mutation
|
| gptkbp:UNII |
6Q1K1VJ0Z1
|
| gptkbp:bfsParent |
gptkb:KRAS_(human)
|
| gptkbp:bfsLayer |
7
|